Dogwood Therapeutics, Inc. (DWTX) — Financial statements
Income statement, balance sheet, and cash flow for Dogwood Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 22↑519.3% | 4↑104.3% | 2↓78.6% | 8↓25.3% | 11 | |
| General & Administrative Expenses | 6↓29.8% | 9↑133.8% | 4↓12.4% | 4↓12.4% | 5 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 6↓29.8% | 9↑133.8% | 4↓12.4% | 4↓12.4% | 5 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 28↑128.7% | 12↑124.5% | 5↓55.8% | 12↓21.3% | 16 | |
| Total Costs & Expenses | 28↑128.7% | 12↑124.5% | 5↓55.8% | 12↓21.3% | 16 | |
| Operating Results | ||||||
| Operating Income | -28↓128.7% | -12↓124.5% | -5↑55.8% | -12↑21.3% | -16 | |
| Depreciation & Amortization | 0.00↓83.1% | 0.01 | 0.00 | 0.00 | 0.00 | |
| EBITDA | -28↓128.4% | -12↓124.8% | -5↑55.8% | -12↑21.3% | -16 | |
| EBIT | -28↓128.2% | -12↓125.0% | -5↑55.8% | -12↑21.3% | -16 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↑100.0% | -0.09↓161.1% | 0.15↑123.6% | 0.07↑1089.6% | 0.01 | |
| Interest Income | 0.00 | 0.00↓100.0% | 0.15↑123.6% | 0.07↑1089.6% | 0.01 | |
| Interest Expense | 0.00↓100.0% | 0.09 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↓100.0% | 0.03 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | -6↓4834.0% | -0.12↓181.5% | 0.15↑123.6% | 0.07↑121.1% | -0.32 | |
| Income Before Tax | -34↓175.6% | -12↓133.2% | -5↑56.8% | -12↑23.3% | -16 | |
| Income Tax Expense | 0.22↑44055.5% | -0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -34↓177.4% | -12↓133.2% | -5↑56.8% | -12↑23.3% | -16 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -34↓177.4% | -12↓133.2% | -5↑56.8% | -12↑23.3% | -16 | |
| Bottom-Line Net Income | -36↓187.6% | -12↓133.2% | -5↑56.8% | -12↑23.3% | -16 | |
| EPS (Basic) | -4.32↑65.5% | -12.52↓77.6% | -7.05↑74.5% | -27.66↑42.3% | -47.90 | |
| EPS (Diluted) | -4.32↑65.5% | -12.52↓77.6% | -7.05↑74.5% | -27.66↑42.3% | -47.90 | |
| Weighted Average Shares | 8↑699.8% | 1↑36.8% | 0.75↑69.6% | 0.44↑32.9% | 0.33 | |
| Weighted Average Diluted Shares | 8↑699.8% | 1↑36.8% | 0.75↑69.6% | 0.44↑32.9% | 0.33 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.